Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL75974 | 0.84 | RIPK1 (0.33) | RIPK1DPP4 | |
| SCHEMBL20702359 | 0.81 | RIPK1 (0.37) | RIPK1DPP4 | |
| SCHEMBL28524745 | 0.80 | RIPK1 (0.33) | RIPK1DPP4 | |
| SCHEMBL1048496 | 0.79 | DPP4 (0.35) | RIPK1DPP4 | |
| SCHEMBL4869792 | 0.79 | RIPK1 (0.32) | RIPK1DPP4 | |
| SCHEMBL5228762 | 0.79 | RIPK1 (0.32) | RIPK1DPP4 | |
| SCHEMBL5078432 | 0.79 | LMNA (0.41) | RIPK1DPP4 | |
| SCHEMBL18046082 | 0.79 | ACE (0.33) | RIPK1DPP4 | |
| SCHEMBL482006 | 0.78 | NCF1 (0.36) | RIPK1DPP4 | |
| SCHEMBL4398466 | 0.77 | LMNA (0.36) | RIPK1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263417-A1 | SUBSTITUTED PYRIMIDO[1,2-B]PYRIDAZINES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | H. LUNDBECK A/S (DK) | 2025-08-21 | — | — | US | disclosed |
| US-12331055-B2 | Substituted pyrimido[1,2-b]pyridazines as positive allosteric modulators of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2025-06-17 | — | — | US | disclosed |
| US-11884676-B2 | Substituted pyrimido[1,2-b]pyridazines as positive allosteric modulators of the muscarinic acetylcholine receptor M4 | VANDERBILT UNIVERSITY (US) | 2024-01-30 | — | — | US | disclosed |
| US-20230286991-A1 | 7-(PIPERIDIN-1-YL)-4H-PYRIMIDO[1,2-B]PYRIDAZIN-4-ONE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2023-09-14 | — | — | US | disclosed |
| US-20230257381-A1 | 7-(PIPERIDIN-1-YL)-4H-PYRIMIDO[1,2-B]PYRIDAZIN-4-ONE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | VANDERBILT UNIVERSITY | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12331055-B2 | Substituted pyrimido[1,2-b]pyridazines as positive allosteric modulators of the muscarinic acetylcholine receptor M4 | CHRM2, CHRM5, CHRM1 | RIPK1 2968/4885DPP4 637/4885 |
| US-20250263417-A1 | SUBSTITUTED PYRIMIDO[1,2-B]PYRIDAZINES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM2, CHRM5, CHRM3 | RIPK1 2780/4885DPP4 930/4885 |
| US-20230286991-A1 | 7-(PIPERIDIN-1-YL)-4H-PYRIMIDO[1,2-B]PYRIDAZIN-4-ONE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM4, CHRM3, CHRM5 | RIPK1 2453/4885DPP4 379/4885 |
| US-11884676-B2 | Substituted pyrimido[1,2-b]pyridazines as positive allosteric modulators of the muscarinic acetylcholine receptor M4 | CHRM2, CHRM5, CHRM3 | RIPK1 2780/4885DPP4 930/4885 |
| US-20230257381-A1 | 7-(PIPERIDIN-1-YL)-4H-PYRIMIDO[1,2-B]PYRIDAZIN-4-ONE DERIVATIVES AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 | CHRM4, CHRM1, CHRM5 | RIPK1 2855/4885DPP4 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.